XML 107 R27.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Interim Consolidated Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2019
Interim Consolidated Financial Information (Unaudited) |
Interim Consolidated Financial Information (Unaudited) | Note 18. Interim Consolidated Financial Information (Unaudited) ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal 2019 Quarter Ended | ​
(in thousands, except per share data) |  | March 31, |  | June 30, |  | September 30, |  | December 31, | ​
Revenues(1) | ​ | $ | 497,857 | ​ | $ | 529,932 | ​ | $ | 551,581 |  | $ | 579,389 | ​
Net income | ​ | $ | 102,312 | ​ | $ | 105,318 | ​ | $ | 128,271 |  | $ | 111,005 | ​
Basic net income per share | ​ | $ | 0.48 | ​ | $ | 0.49 | ​ | $ | 0.60 | ​ | $ | 0.51 | ​
Diluted net income per share | ​ | $ | 0.47 | ​ | $ | 0.48 | ​ | $ | 0.59 | ​ | $ | 0.51 | ​
Shares used in computation of basic net income per share | ​ |  | 214,065 | ​ |  | 214,620 | ​ |  | 215,199 |  | ​ | 215,770 | ​
Shares used in computation of diluted net income per share | ​ | ​ | 217,061 | ​ | ​ | 217,483 | ​ | ​ | 217,791 | ​ | ​ | 218,542 | ​
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal 2018 Quarter Ended | ​
(in thousands, except per share data) |  | March 31, |  | June 30, |  | September 30, |  | December 31, | ​
Revenues(2) | ​ | $ | 382,282 | ​ | $ | 521,516 | ​ | $ | 449,683 |  | $ | 528,402 | ​
Net income (loss) | ​ | $ | (41,140) | ​ | $ | 52,394 | ​ | $ | 29,176 |  | $ | 69,063 | ​
Basic net income (loss) per share | ​ | $ | (0.19) | ​ | $ | 0.25 | ​ | $ | 0.14 | ​ | $ | 0.32 | ​
Diluted net income (loss) per share | ​ | $ | (0.19) | ​ | $ | 0.24 | ​ | $ | 0.14 | ​ | $ | 0.32 | ​
Shares used in computation of basic net income (loss) per share | ​ |  | 211,681 | ​ |  | 212,210 | ​ |  | 212,627 |  | ​ | 213,013 | ​
Shares used in computation of diluted net income (loss) per share | ​ | ​ | 211,681 | ​ | ​ | 215,103 | ​ | ​ | 215,964 | ​ | ​ | 216,042 | ​
(1) | The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $396.2 million, $433.9 million, $454.0 million, and $490.8 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $61.6 million, $76.0 million, $80.1 million and $88.6 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In December 2018 and July 2019, we entered into collaborative research and license agreements with Innovent and Zai Lab, respectively. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $40.0 million, $20.0 million, $17.5 million and $0.0 million, respectively, of milestone and contract revenues relating to these agreements.
(2) | The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $334.5 million, $365.5 million, $367.7 million, and $399.2 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $47.7 million, $56.0 million, $61.9 million and $69.2 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $0.0 million, $100.0 million, $20.0 million and $60.0 million, respectively, of milestone and contract revenues relating to these agreements.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration